Roche's Invirase (saquinavir) expanded access lottery to be managed by Parexel.
Executive Summary
ROCHE INVIRASE (SAQUINAVIR) EXPANDED ACCESS LOTTERY MANAGED BY PAREXEL will register HIV-positive patients to be selected for 2,280 available U.S. slots to receive the protease inhibitor, Hoffmann-La Roche announced June 21. Patients who have failed prior antiviral treatment may be registered by their physicians until 5 p.m. July 21, after which a lottery is to be conducted. Invirase will be shipped free of charge to the lottery selectees in August.